Following on from information provided to NICE by the company in April 2019, the appraisal of Pembrolizumab for treated oesophageal or gastro-oesophageal junction cancer [ID1357] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1357 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Stakeholders
| Companies sponsors | Merck Sharp & Dohme (pembrolizumab) |
| Others | Department for Health and Social Care |
| NHS England | |
| Welsh Government | |
| Professional groups | Association of Cancer Physicians |
| Cancer Research UK | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Comparator companies | Accord Healthcare (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) |
| Actavis UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) | |
| Celgene (paclitaxel) (not signed confidentiality agreement) | |
| Hospira UK (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) | |
| Medac GmbH (docetaxel, paclitaxel, irinotecan) (not signed confidentiality agreement) | |
| Pfizer Ltd (irinotecan) (not signed confidentiality agreement) | |
| Sanofi (docetaxel) (not signed confidentiality agreement) | |
| Seacross Pharmaceuticals (docetaxel, irinotecan) (not signed confidentiality agreement) | |
| Shire Pharmaceuticals (irinotecan) (not signed confidentiality agreement) | |
| General commentators | All Wales Therapeutic and Toxicology Centre |
| British National Formulary | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Scottish Medicines Consortium | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Institute of Cancer Research |
| National Cancer Research Institute |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 08 November 2022 | Discontinued. Following on from information provided to NICE by the company in April 2019, the appraisal of Pembrolizumab for treated oesophageal or gastro-oesophageal junction cancer [ID1357] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 16 September 2019 | The company has informed NICE that it will not provide an evidence submission for this appraisal. Therefore, we are suspending the appraisal while we consider the next steps. |
| 11 April 2019 | Suspended. Appraisal suspended |
| 07 March 2019 | Invitation to participate |
| 04 April 2018 - 02 May 2018 | Consultation on suggested remit, draft scope and provisional matrix of consultees and commentators |
| 01 March 2017 | In progress. DH Referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual